Kaya Holdings (OTCQB:KAYS) Closes Additional Round of Non-Dilutive Bridge Financing Targeted to Complete The Sacred Mushroom(TM) Psilocybin Treatment Center
KAYS' Oregon Based Psilocybin Treatment Center is on track to be the first of its kind operated by a U.S. Public CompanyFT. LAUDERDALE, FL / ACCESSWIRE / October 18, 2023 / Kaya Holdings, Inc., ("KAYS" or the "Company") (OTCQB:KAYS) announced today …
KAYS' Oregon Based Psilocybin Treatment Center is on track to be the first of its kind operated by a U.S. Public Company
FT. LAUDERDALE, FL / ACCESSWIRE / October 18, 2023 / Kaya Holdings, Inc., ("KAYS" or the "Company") (OTCQB:KAYS) announced today that it has closed an additional round of bridge financing targeted to complete KAYS' planned psilocybin treatment center in Portland, Oregon. The facility will operate under the name "The Sacred Mushroom.
Total funds received from our bridge financing since the first installment was received in June 2023, are $600,000, with no commissions or fees associated with the financing. The funds are not convertible into KAYS stock. $100K of the funds are in the form of short-term financing with repayment due March 15, 2023, and $500K is due to be repaid from 10% of KAYS' revenues quarterly, with any unpaid balance due June 30, 2025.
We believe that KAYS is presently the only U.S. public company engaged in securing an Oregon Health Authority ("OHA") license to open a psilocybin treatment center, aiming to create a setting that is unmatched by any other facility and providing access to relief from treatment-resistant mental health conditions, including depression, anxiety, additions, and eating disorders.
Our Treatment Model
A recently published report on psilocybin treatment prices in Oregon showed that Initial prices for one facility range from $300 for a group microdose session to $3,500 for an individual high-dose
session, with another facility pricing first-time full-dose treatments at $15,000 (these prices do not include the cost of the psilocybin, which can run from $300 to $500).
Lesen Sie auch
KAYS expects its planned model facility to offer a superior setting, broader activity and treatment options, integrated cultivation and processing, and accessible pricing, thereby enabling us to deliver a superior treatment experience at a much lower price than the competition, while still achieving profitability.